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General methods 
General: Reagents and solvents were purchased from commercial suppliers (Aldrich, Fluka or Merck) and were 
used without further purification. Flash chromatographic purifications and preparative reversed-phase 
purifications were performed on a Biotage® Isolera PrimeTM equipment. TLCs were performed using 6x3 cm 
SiO2 pre-coated aluminium plates (ALUGRAM® SIL G/UV254).  
Nuclear Magnetic Resonance (NMR): Spectroscopic experiments for the characterization of compounds were 
carried out on a Varian Mercury 400 instrument (400 MHz for 1H and 101 MHz for 13C). Chemical shifts (δΗ) are 
quoted in parts per million (ppm) and referenced to the appropriate NMR solvent peak(s). 2D-NMR 
experiments COSY, HSQC and HMBC were used where necessary in assigning NMR spectra. Spin-spin coupling 
constants (J) are reported in Hertz (Hz). For the experiments performed in aqueous buffer a low molecular 
weight heparin was used: dp14 (from Iduron, prepared by high resolution gel filtration of partial heparin lyase 
digestion of high quality heparin, MW average ~ 4100). One- and two-dimensional (1D and 2D) NMR 
experiments were performed at 298 K on a 500 MHz Bruker AVANCEIII-HD equipped with a z-gradient (65.7 G 
cm-1) inverse TCI-cryoprobe. Samples were dissolved in  5 mM Tris-d11 buffer with 50 mM NaCl (in D2O, pH 
7.5, uncorrected pH meter reading). Bruker TopSspin 3.5pl6 standard pulse sequences were used for 1D and 
2D experiments. 2D 1H-1H experiments, TOCSY with zero-quantum suppression (DIPSI2GPPHZS, TM=70ms), 
NOESY with zero-quantum suppression (NOESYGPPHZS, TM=200ms) and TROESY (ROESYGPPH19.2, 
TM=250ms) were adquired for 3AL with and without dp14 heparin. Also, for 3AL compound, 2D 1H-13C 
(HSQCETGPSISP2 and HMBCETGPL3ND) experiments were acquired. For full-length heparin-3AL titration 
(Figure S9), the CPMG spin-echo pulse sequence with pre-saturation (CPMGPR1D) was used, which follows 
the scheme: recycle delay – [–90– (τ – 180 – τ )n – FID],  with a τ = 'variable'  and n = 'variable' (for a fixed 
CPMG loop cycle) as a T2-filter; these experiments were acquired with n fixed to 6 cycles and a τ value of 1ms. 
Liquid Chromatography coupled to Mass Spectrometry: Analyses were carried out at the IQAC Mass 
Spectrometry Facility, using a UPLC-ESI-TOF equipment: [Acquity UPLC® BEH C18 1.7 mm, 2.1x100 mm, LCT 
Premier Xe, Waters]. (CH3CN + 20 mM HCOOH and H2O + 20 mM HCOOH) mixtures at 0.3 mL/min were used 
as mobile phase.  
Fluorescence spectroscopy: Fluorescence emission and excitation spectra were collected on a Photon 
Technology International Instrument, the Fluorescence Master Systems, using the Software Felix32 and 
cuvettes with 10 mm path length. 
Dynamic covalent chemistry assays for the heparin ligand screening 
A stock solution of imines was prepared by dissolving the necessary amounts of spermine and the aromatic 
aldehydes in MeOH rendering a final concentration of 10 mM in all the reagents. Then, two reaction mixtures 
were prepared in separate eppendorfs from the same stock solution of the imines by mixing 10 L of the imine 
stock solution with 90 L of a solution of 5mM NaBH3CN in aqueous 50 mM Tris Buffer at pH 7.5 (1mM final 
concentration of both spermine and each of the aldehydes) either in the absence or the presence of 1.2 mg of 
heparin (1 mM final concentration of heparin, ~17-18 mM on repeating unit). The mixtures were allowed to 
react at room temperature for 24 hours and after that quenched with 50 L of 2M HCl, two-fold diluted with 
water and analyzed by UPLC-MS. The assignment of the peaks observed in the reactions was done on the basis 
of the m/z values and confirmed by injection of samples obtained from deconvoluted sublibraries. The 
amplification factors were calculated by dividing the normalized areas of the corresponding HPLC peaks in the 
presence of heparin (AT) by the areas obtained in the absence of heparin (Ao). The results shown in Figure 1C 
of the manuscript are the average of three independent assays under the optimized reaction conditions. 
The observed species were assigned by ion-detection UPLC-MS experiments. 
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Figure S1. Ion-selective HPLC traces for each library member obtained from the reductive amination reaction 
in the absence of heparin. The two numbers on the right corner of each chromatogram correspond to the m/z 
values and the peak area, respectively. 
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Figure S2. Ion-selective UPLC traces for selected library members obtained from the reductive amination 
reaction in the presence of heparin. The most amplified members are shown. 
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Preparative scale synthesis of the dialkylated spermine derivatives 
Synthesis of symmetric compounds (3AA and 3LL) 
Synthesis of 3AA:  
 
To a spermine (81 mg, 0.4 mmol) solution in MeOH (2 mL) a solution of salicylaldehyde (84 µL, 0.8 mmol) in 
MeOH (1 mL) was added drop by drop. The resulting reaction mixture was stirred overnight at ambient 
temperature. Then, NaBH4 (120 mg, 8 eq) was added and the reaction was stirred for 6 hours. After addition 
of H2O (1 mL) and HCl 2N (2 mL), the reaction mixture was stirred for 3 hours, evaporated and purified by 
reverse phase chromatography with a gradient of ACN (1% TFA) and water (1% TFA) to yield 134 mg (0.15 
mmol, 38%) as a TFA salt with 95% purity. 
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1H-NMR (MeOD, 400 MHz): δ (ppm) 7.39-7.15 (m, 4H, H10,12), 7.03-6.78 (m, 4H, H9, 10), 4.22 (s, 4H, H1), 
3.18-3.09 (m, 8H, H2,4), 3.07 (m, 4H, H5), 2.16 (m, 4H, 3H), 1.80 (m, 4H, H6) 13C-NMR (MeOD, 100 MHz): δ 
(ppm) 156.1 (C8), 131.1 (C10), 131.0 (C12), 119.6 (C11), 117.0 (C7), 114.9 (C9), 46.7 (C5), 46.6 (C1), 44.4 (C4), 
43.8 (C2), 22.8 (C6), 22.5 (C3) HRMS for C24H39N4O2: Calculated: 415.3073 (M+H)+; found: 415.3056. 
HPLC and HRMS 
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Synthesis of 3LL:  
 
To a spermine (81 mg, 0.4 mmol) solution in MeOH (2 mL) a solution of 1-naphthylaldehyde (108 µL, 0.8 mmol) 
in MeOH (1 mL) was added. The resulting reaction mixture was stirred overnight at ambient temperature. 
Then, NaBH4 (120 mg, 8 eq) was added and the reaction was stirred for 6 hours. After addition of H2O (1 mL) 
and HCl 2N (2 mL), the reaction mixture was stirred for 3 hours, evaporated and purified by reverse phase 
chromatography with a gradient of ACN (1% TFA) and water (1% TFA) to yield 30 mg (0.03mmol, 8%) of product 
as a TFA salt with 95% purity, because the mono-substituted product is obtained during the reaction. 
N
H
N
H
H
N
H
N
1 2
3
4 5
6
7
8
9
10
11
12
13
14
15
16
 
1H-NMR (MeOD, 400 MHz): δ (ppm) 8.16 (d, J = 8.5 Hz, 2H, H15), 8.01 (dd, J = 10.0, 8.5 Hz, 4H, H10,12), 7.68 
(ddd, J = 8.5, 7.0, 1.0 Hz, 4H, H8,14), 7.61 (ddd, J = 8.0, 7.0, 1.0 Hz, 2H, H13), 7.57 (dd, J = 8.0, 7.0 Hz, 2H, H9), 
4.72 (s, 4H, H1), 3.29 (m, 4H, H2), 3.14 (m, 4H, H4), 3.07 (t, J = 6.8 Hz, 4H, H5), 2.18 (, 4H, H3), 1.79 (m, 4H, H6) 
13C-NMR (MeOD, 100 MHz): δ (ppm)  135.5 (C7), 132.6 (C11), 131.8 (C12), 130.4 (C8), 130.2 (C10), 128.5 (C14), 
128.3 (C16), 127.7 (C13), 126.5 (C9), 123.7 (C15), 49.3 (C1), 48.1 (C5), 45.9 (C2), 45.8 (C4), 24.2 (C6), 24.1 (C3) 
HRMS for C32H42N4: Calculated: 483.3488 (M+H)+; found: 483.3482 
HPLC and HRMS 
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Synthesis of asymmetric compound 3AL 
 
Monoalkylated spermine with aldehyde L (3L): To an ice-solution of spermine (121 mg, 0.6 mmol) in 
anhydrous THF (2 mL), a solution of 1-naphthylaldehyde (54 µL, 0.4 mmol) was added dropwise. The resulting 
reaction mixture was stirred at ambient temperature overnight. Then NaBH3CN (201 mg, 3.2 mmol) was added 
and the reaction was stirred overnight. After the addition of 1 mL of H2O, the reaction was stirred one hour, 
and then 2mL of HCl (2N) were added and the reaction mixture was stirred for two more hours. The crude was 
purified by reverse phase chromatography leading 44 mg (0.07 mmol, 18% yield) of final product as a TFA salt. 
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1H-NMR (MeOD, 400 MHz): δ (ppm) 8.17 (d, J = 8.5 Hz, 1H, H20), 8.10-7.94 (m, 2H, H15,17), 7.80-7.64 (m, 2H, 
H13,19), 7.64-7.50 (m, 2H, H14,18), 4.72 (s, 2H, H11), 3.3 (m, 2H, H10), 3.20-3.10 (m, 4H, H3,8), 3.10-3.0 (m, 
6H, H1,4,7), 2.19 (m, 2H, H9), 2.09 (m, 2H, H2), 1.80 (m, 4H, H5,6 13C-NMR (MeOD, 100 MHz): δ (ppm) 135.5 
(C12), 132.7 (C16), 131.7 (C17), 130.4 (C21), 130.3 (C19), 130.2 (C15), 128.5 (C13), 127.7 (C18), 126.5 (C14), 
123.8 (C20), 49.3 (C11), 48.2 (C4,7), 46.1 (C10), 45.9 (C3,8), 37.8 (C1), 25.4 (C2), 24.2 (C5,6), 24.1 (C9) HRMS 
for C21H34N4: Calculated: 343.2862 (M+H)+; found: 343.2820. 
HPLC and HRMS 
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Synthesis of 3AL: To a solution of the amine 3L (44mg, 0.07 mmol) in 1 mL of Tris buffer at pH 7.5, TEA (20 µL, 
2eq) and salicylaldehyde (6.5 µL, 0.06 mmol) were added. The mixture was stirred overnight at room 
temperature. Then NaBH4 (10 mg, 4 eq) was added and the reaction mixture was stirred for 6 hours. 
The reaction was treated with HCl 2N (2 mL) and stirred for two hours, after evaporating the solvent, it was 
purified by reverse phase chromatography using a gradient of ACN (1%TFA) and water (1% TFA) to yield 10 mg 
(0.01 mmol, 18%) of the final product as a TFA salt. 
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1H-NMR (MeOD, 400 MHz): δ (ppm) 8.17 (d, J = 8.0 Hz, 1H, H27), 8.01 (dd, J = 10.0, 8.5 Hz, 2H, H22,24), 7.79-
7.65 (m, 2H, H20,26), 7.64-7.49 (m, 2H, H21,25), 7.29 (m, 2H, H3,5), 6.91 (m, 2H, H2,4), 4.75 (s, 2H, H18), 4.22 
(s, 2H, H7), 3.31 (m, 2H, H17), 3.14 (m, 6H, H8,10,15), 3.08 (m, 4H, H11,14), 2.17 (m, 4H, H9,16), 1.79 (m, 4H, 
H12,13)  13C-NMR (MeOD, 100 MHz): δ (ppm) 157.5 (C1), 135.5 (C19), 132.7 (C23), 132.6 (C3), 132.5 (C5), 
131.8 (C24), 130.4 (C20), 130.2 (C22), 128.5 (C26), 128.2 (C28), 127.7 (C25), 126.5 (C21), 123.7 (C27), 121.1 
(C4), 118.5 (C6), 116.4 (C2), 49.2 (C18), 48.2 (C7), 48.2 (C11,14), 45.9 (C17), 45.8,45.2 (C8,10,15), 24.2 (C12,13), 
24.1 (C16), 23.9 (C9) HRMS for C28H40N4O: Calculated: 449.328 (M+H)+; found: 449.3281. 
HPLC and HRMS 
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Fluorescence titration experiments 
Stock solutions of the corresponding ligand (49 M) and heparin (0.4 mM in the disaccharide repeating unit) 
were prepared in 5 mM Tris buffer at pH 7.5. 2 mL of the ligand solution was placed on a quartz cell and the 
emission fluorescence spectrum was measured upon excitation at 280 nm. Then, small volumes of the heparin 
stock solution were added to the cell, and the fluorescence spectra was acquired after each addition. The 
normalized relative fluorescence increase of the intensity at 400 nm was plotted against the equivalents of 
heparin added, considering the concentration of the repeating disaccharide unit. The titration isotherm 
showed a complex shape that was impossible to reliably fit to a reasonable binding model. However, the 
qualitative comparison between the 3AL and 3LL curves showed a stronger interaction of heparin with 3AL. 
Thus, the titration of 3AL reaches the maximum fluorescence change at 2.5 equivalents of repeating units of 
1, while the curve for 3LL is still growing at 4 equivalents of repeating units of 1. Moreover, the steepness of 
the titration isotherm of 3AL is much larger than that of 3LL, suggesting a higher degree of complex formation 
with equivalent proportion of added heparin. 
 
 
Figure S3. Fluorescence titration curves for 3AL (blue) and 3LL (green) upon addition of 1 
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Isothermal Titration Calorimetry experiments 
ITC was performed in a MicroCal VP-ITC instrument (GE Healthcare) in 5 mM Tris-HCl buffer pH 7.5 at 298 K. 
The cell (volume ~ 1.4 mL) contained 80 µM of the ligand while the syringe (volume ~ 0.3 mL) contained 200 
μM heparin (considering the average molecular weight of the corresponding polysaccharide). Experimental 
conditions were as follows: a first injection of 2 μL followed by 40 injections of 5 μL with a spacing of 180 s 
between injections, and a stirring speed of 300 rpm. A blank titration was performed by injecting buffer into 
the products in the same conditions. Raw data were analyzed with the MicroCal Origin software (OriginLab, 
Northampton, MA, USA) using a one-site model for the fittings. 
For the calculation of the molar concentration of heparin, we considered the averaged MW of the specific 
heparin used (12 kD), despite it was polydisperse. The influence of the heparin heterogeneity on the 
determined parameters was not limiting in our case, since our objective was to estimate the affinity and to 
compare the results for the different ligands under the same conditions. 
ITC experiments with 3AL 
 
Figure S4. Raw data (up) and processed data (down) for two ITC experiments of 3AL with heparin. 
The ITC curves showed an exothermic process in the initial titration points and a consistent endothermic 
process after a certain point of the titration. This behavior has been previously observed in the titration of 
N
H
N
H
H
N
H
N
OH
0.00 20.00 40.00 60.00 80.00 100.00 120.00
-1.0
-0.5
0.0
0.5
1.0
Time (min)
µ
c
a
l/
s
e
c
0.00 20.00 40.00 60.00 80.00 100.00 120.00 140.00
12.8
13.0
13.2
13.4
13.6
13.8
14.0
14.2
14.4
14.6
Time (min)
µ
c
a
l/
s
e
c
0.0 0.1 0.2 0.3 0.4 0.5 0.6
-2
0
2
4
6
8
10
12
14
Data: MC323a_NDH
Model: OneSites
Chi^2/DoF = 4.094E5
N 7.50 ±0.107
K 8.34E5 ±1.80E5
H 1858 ±41.95
S 33.3
 MC323a_NDH
 MC323a_Fit
Molar Ratio
k
c
a
l/
m
o
le
 o
f 
in
je
c
ta
n
t
0.0 0.1 0.2 0.3 0.4 0.5 0.6
-2
0
2
4
6
8
10
12
14
Data: MC323b_NDH
Model: OneSites
Chi^2/DoF = 3.830E5
N 7.32 ±0.110
K 6.89E5 ±1.39E5
H 1969 ±46.32
S 33.3
 MC323b_NDH
 MC323b_Fit
Molar Ratio
k
c
a
l/
m
o
le
 o
f 
in
je
c
ta
n
t
S20 
 
GAGs with cationic peptides[1] and peptidomometics,[2] and can be ascribed to an initial non-specific 
aggregation process by purely electrostatic interactions. In this case, we have confirmed this aggregation with 
two additional independent experiments. First, the 1H NMR titration of 3AL with non-fractioned heparin, using 
a relaxation-filtering pulse sequence (Figure S12) showed the disappearance of the NMR signals of 3AL in the 
first titration points, which is consistent with the formation of very large species in solution with a very fast 
cross-relaxation (short T2 and thus efficiently filtered with the CPMG sequence). The signals of the 3AL ligand 
were recovered upon further addition of heparin, suggesting the formation of discrete species with smaller 
apparent sizes. These discrete species would correspond to the ligand-to-heparin ratios of the consistent 
endothermic process observed in the ITC curves. 
In order to confirm this hypothesis, we have measured the dynamic light scattering (DLS) of samples containing 
3AL and 1 at relative concentrations similar to those of the first points of the ITC titrations (20 µM of 3AL and 
0.2 µM of heparin, corresponding to 3.4-3.6 µM in the disaccharide repeating unit). The DLS data confirmed 
the formation of very large species of a hydrodynamic radius of 61 ± 4 nm and a polydispersity of 0.3 ± 0.2. 
The DLS of the corresponding samples of either 3AL or heparin alone showed no scattering in separate control 
experiments. Thus, we concluded that the first points of the titration experiments correspond to large 
aggregates formed by non-specific electrostatic interactions between 3AL and 1 and, accordingly, we used just 
the endothermic points for the fitting. Despite this is an oversimplification of the true process, we considered 
that the obtained data can be used for comparison purposes. 
 
Figure S5. Size distribution obtained by DLS analysis of a sample containing 3AL (20 µM) and 1 (0.2 µM, 3.4-
3.6 µM in the disaccharide repeating unit). The analyses of five replicates are shown. 
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ITC experiments with 3LL 
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Figure S6. Raw data for two ITC experiments of 3LL with heparin. 
 
In this case, we were unable to fit the observed heat change to any available binding model. Moreover, the 
shape of the heat peaks during the experiment suggested a weaker and less specific interaction with heparin. 
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ITC experiments with 3AA 
 
Figure S7. Raw data (up) and processed data (down) for two ITC experiments of 3AA with heparin. 
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ITC results 
Despite the fitting for 3AA was not very accurate, we used the obtained values for comparison (Table S1). The 
results obtained from the fitting of the data for 3AL and 3AA clearly showed that 3AL is a stronger binder to 
heparin, by at least one order of magnitude in the affinity (Kd) and a more favorable Gibbs energy (ca. 2 
kcal/mol). Moreover, the apparently larger stoichiometry with 3AA also reflects a less efficient interaction. 
 
Table S1: Thermodynamic parameters obtained by fitting the ITC data to a simple one-site binding mode: 
 3AL 3AA 
N 7.5±0.1 7.3±0.1 15.5±12 14.2±8 
Kassociation (M-1) 8.34·105±1.8·105 6.89·105±1.4·105 4.44·104±2.9·104 4.43·104±3.5·104 
Kdissociation (M) 1.20±0.20 1.45±0.20 22.5±8.9 22.5±9.9 
ΔH (cal·mol-1) 1858±42 1969±46 3870±2340 2647±914 
ΔS (cal·K-1·mol-1) 33.3 33.3 34.3 30.1 
ΔG (cal·mol-1) -8065 -7954 -6351 -6333 
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NMR binding experiments 
NMR characterization of 3AL in aqueous buffer  
 
 
 
Figure S8. 1H-13C HMBC spectrum of compound 3AL 1 mM (500 MHz, 5 mM Tris-d11 and 50 mM NaCl in D20, 
pH 7.5) and chemical structure of 3AL with labelling numbers used in the NMR assignment.  
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Figure S9. 1H-13C HSQC spectrum of compound 3AL 1 mM (500 MHz, 5 mM Tris-d11 and 50 mM NaCl in D20, 
pH 7.5) and chemical structure of 3AL with labelling numbers used in the NMR assignment. 
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Figure S10. 1H-1H TOCSY spectrum of compound 3AL 1 mM (500 MHz, 5 mM Tris-d11 and 50 mM NaCl in D20, 
pH 7.5). 
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Figure S11. 1H-1H NOESY spectrum of compound 3AL 1 mM (500 MHz, 5 mM Tris-d11 and 50 mM NaCl in D20, 
pH 7.5). 
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3AL-heparin interaction studies by NMR 
 
 
Figure S12. 1H CPMGPR1D NMR spectra of compound 3AL in the presence of increasing amounts of heparin. 
The concentrations of the heparin are referred to the concentration of the disaccharide repeating unit, 
considering the average molecular weight and the composition of the heparin sample here used. All spectra 
were acquired at 500 MHz in 5 mM Tris-d11 and 50 mM NaCl in D20, pH 7.5.  
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3AL-dp14 heparin interaction studies by NMR 
 
Figure S13. Selected regions of the 1H NMR spectra of: (a) compound 3AL (0.55 mM) (c) dp14 heparin (2.8 mM 
in the corresponding disaccharide repeating unit) and (b) mixture of 3AL and dp14. All spectra were acquired 
at 500 MHz in 5 mM Tris-d11 and 50 mM NaCl in D20, pH 7.5.  
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Figure S14. 1H-1H TOCSY spectrum (500 MHz, 5 mM Tris-d11 and 50 mM NaCl in D20, pH 7.5) of compound 
3AL (0.55 mM) in the presence of dp14 heparin (2.8 mM in the corresponding disaccharide repeating unit). 
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Figure S15. 1H-1H TROESY spectrum (500 MHz, 5 mM Tris-d11 and 50 mM NaCl in D20, pH 7.5) of compound 
3AL (0.55 mM) in the presence of dp14 heparin (2.8 mM in the corresponding disaccharide repeating unit). 
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Blood coagulation factor enzymatic assays 
Recombinant antithrombin III and coagulation Factor Xa were obtained from the Berichrom Heparin test, 
supplied by SIEMENS. Following the indications of the test kit, stock solutions were prepared as follows: 
Human antithrombin III (1 IU/mL), Factor Xa reagent (0.4 µg/mL, human plasma fraction with the additives 
Tris, sodium chloride and EDTA) and a chromogenic substrate specific for factor Xa (4 mM of Z-D-Leu-Gly-Arg-
ANBA-methyl amide). On the other hand, 4-nitroaniline (Sigma Aldrich) was added to the substrate solution 
at a concentration of 1.6 mM and was used as internal standard to quantify the cleavage of the chromogenic 
substrate. Heparin (sodium salt from porcine intestinal mucosa, polydisperse, from 6000 to 30000 Daltons) 
was purchased from Sigma-Aldrich. All compounds were dissolved in miliQ water at the desired stock 
concentrations prior to start the assays and kept at 4 ֯C.  
Various concentrations of the ligand (3AL or 3AA), heparin (0.4 IU/mL or 0.6 IU/mL), human antithrombin III 
solution (10 µL) and Factor Xa reagent solution (100 µL) were added in that order in an Eppendorf and brought 
to a total volume of 120µL. Then, 40 L of Reagent Substrate solution was added to start the experiment and 
the mixture was vigorously shaken at 25 ֯C. 20 µL samples were taken at minutes 5/10/15/20/30/50/80/120, 
diluted with 40 µL of acetic acid (20% v/v), and injected in the analytical HPLC. The gradient ranged from 5% 
of ACN (0.1% formic acid) in water (0.1% formic acid) to 100% of ACN in 24 minutes using a 15 x 4.6 mm 
KROMAPHASE C18 5.0 µm column (retention time of cleaved chromophore 9.1 min, retention time of 
chromogenic substrate 13.9min, retention time of 4-nitroaniline 15.4min). 
FXa/ATIII activity was represented as percent of hydrolysis, which was calculated from the normalized area of 
cleaved peptide at 405 nm at each corresponding time point. Experiment carried out in absence of heparin 
was considered as maximum of activity while experiment with heparin and no ligand was considered as 
negative control (maximum inhibition of FXa by heparin). Concentration of heparin was selected for the 
measurement to render a significant inhibition within experimental time, while allowing the reaction to 
proceed. 
 
 
Figure S16. Typical HPLC traces showing the progression of the hydrolysis reaction 
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ANBA-NHMe
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Figure S17. Plot of the percent of the hydrolysis of the Z-D-Leu-Gly-Arg-NMe-AMBA peptide (measured by 
HPLC at 405 nm) catalyzed by the FXa/ATIII system in the absence (black) or in the presence of 0.6 IU/mL 1 
(brown). Increasing concentrations of the ligand 3AL (green 8 M, blue 24 M, red 60 M) produces an 
increase of the rate of the hydrolysis of the peptide, which is lower than in the presence of a smaller amount 
of heparin (compare with Figure 4B of the manuscript). 
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Another control experiment was performed with 3AL. A reaction was carried out with 0.4 IU/mL of heparin 
and 8 µM 3AL, also containing ATIII, FXa and the peptide substrate Z-D-LGR-N(Me)ANBS. The additional 
background reactions without heparin (maximum activity of FXa enzyme) or with heparin but without 3AL 
(maximum inhibition of FXa by heparin) were also done within the same batch. The percent of hydrolysis was 
monitored at different time points as in the previous cases. After 120 minutes, a 50% additional heparin was 
added to the two reactions that initially contained heparin (with/without 3AL), whereas new fresh substrate 
was added to the three reaction vessels, and the evolution of the hydrolysis was monitored for other 120 
minutes. The normalized hydrolysis of the peptide substrate (corrected considering the amount of hydrolyzed 
substrate already present in the reaction) showed that the presence of additional heparin induced a much 
efficient inhibition of the FXa enzyme. These results unambiguously show that the ligand 3AL only binds 
heparin and has no other unexpected effects on the enzymatic assay. 
 
 
Figure S18. Plot of the percent of the hydrolysis of the Z-D-Leu-Gly-Arg-NMe-AMBA peptide (measured by 
HPLC at 405 nm) catalyzed by the FXa/ATIII system in the absence (black) or in the presence of 0.4 IU/mL of 1 
(blue). Addition of the ligand 3AL (red 8 M) induced the partial recovery of the enzymatic activity. At 120 
min, additional heparin (+0.2 IU/mL) was added to the two reactions that already contained heparin, whereas 
peptide substrate was added to all the reactions. The percent of the hydrolysis of the substrate (normalized 
and corrected) showed a decrease of the enzymatic activity. 
  
+ 0.2 IU/mL heparin
+ 0.4 IU/mL heparin
+ 40 L of Reagent Substrate 
(4 mM Z-D-LGR-N(Me)ANBA)
+ 40 L of Reagent Substrate 
(4 mM Z-D-LGR-N(Me)ANBA)
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Molecular Dynamics Simulation Methods 
All molecular simulations were carried out with the package Schrödinger Suite 2017,[3] through its graphical 
interface Maestro.[4] The program Macromodel,[5] with its default force field OPLS3[6] and GB/SA water 
solvation conditions,[7] was used for energy minimization. Molecular dynamics simulations were performed 
with the program Desmond,[8] using the OPLS3 force field. A heparin hexadecamer model (dp16) was derived 
from residues 3-19 of chain A of the reported solution structure of heparin DP36 (PDB 3IRL).[9] Ligand 3AL was 
built within Maestro. Heparin dp16 was modelled with all its sulfate and carboxylate groups in their ionized 
state (-32 total charge), while the 3AL ligand was modelled with its four amino groups protonated, as suggested 
by pKa calculations carried out with Epik.[10] Both structures were energy minimized before building the 
simulation system. To approach the high stoichiometric ratio of the heparin-3AL complex determined in our 
ITC experiments, a system composed of a dp16 molecule plus five unbound and arbitrarily placed 3AL 
molecules was set up in a cubic box whose sides were at 15 Å of the closest solute atom, with added Na+ ions 
to reach neutrality and the whole system solvated with TIP3P water (~26300 TIP3P molecules), using the 
System Builder of the Maestro-Desmond interface.[11] 
The full system (~80000 atoms) was subjected to steepest descent minimization, first with the solute restrained 
and then without restraints until a gradient threshold of 0.1 kcal/mol/Å was reached. Then it was heated 
stepwise until 300 K with short MD runs under periodic boundary conditions (PBC, NPT, Berendsen thermostat-
barostat) (12 ps at 0.1, 10, 100 and 300 K), and equilibrated for 2 ns at the last temperature and 1.0 bar in the 
NPT ensemble. A production MD simulation (500 ns, 2 fs time step) was performed under the same conditions 
(PBC, NPT ensemble, 300 K and 1.0 bar) using the Nose-Hoover thermostat method[12] with a relaxation time 
of 1.0 ps and the Martyna-Tobias-Klein barostat method[13] with isotropic coupling and a relaxation time of 2 
ps. Integration was carried out with the RESPA integrator[14] using time steps of 2.0, 2.0, and 6.0 fs for the 
bonded van der Waals and short range and long range electrostatic interactions, respectively. A cut-off of 9 Å 
was applied to van der Waals and short-range electrostatic interactions, while long-range electrostatic 
interactions were computed using the smooth particle mesh Ewald method with an Ewald tolerance of 10-9.[15] 
Bond lengths to hydrogen atoms were constrained using the Shake algorithm.[16] Coordinates were saved every 
200 ps, hence 2500 snapshots (frames) were obtained. The Simulation Event Analysis application included in 
the Desmond-Maestro interface and different ad-hoc scripts were used to analyze the simulations results. The 
2500 snapshots were clustered based on the atomic RMSD of the heavy atoms using the hierarchical clustering 
with average linkage method implemented in the Schrodinger Suite and fixing the number of clusters to 10.  
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Figure S19. Snapshots from the 500 ns MD simulation of a system containing one dp16 heparin model 
(spheres) and five 3AL (green sticks) molecules. Water molecules and ions are omitted for clarity.  
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Figure S20. Results from clustering the 2500 snapshots obtained from molecular dynamics, by applying a 
hierarchical clustering method with 10 clusters. The graph shows the population distribution among the 
clusters (red bars, left axis) and the accumulated % of population (blue line, right axis). 
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Figure S21. Results from molecular dynamics. For each of the five 3AL molecules in the simulation, the graphics 
show the dependence on simulation time of: (1) the number of hydrogens bonds established with dp16 
(averages for the whole simulation: 3.5±1.5 (3AL_1), 4.0±1.4 (3AL_2), 3.8±1.4 (3AL_3), 3.6±1.6 (3AL_4) and 
3.8±1.6 (3AL_5)) and (2) the minimum distance (Å) between protons on positions A3 and A5, A4 and A6, A3* 
and A5*, and A4* and A6*. 
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